The cross talk between the cyclinD1-CDK4/6-pRb axis and PI3K/AKT/mTOR pathway has always been regarded as more obvious in hormonal receptor-positive and HER2-positive cancers, as ER can directly target cyclin D1 transcriptionally and activate CDK4/6-pRb. The gene discussed is ERBB2; the disease is cancer.